From: Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours
Study Title | Phase protocol's ID | Sponsor/lead organisations | Important points | Primary objective |
---|---|---|---|---|
Phase I/II partially randomised study of Hedgehog antagonist GDC-0449 in combination with γ- Secretase Inhibitor RO4929097 in patients with advanced or metastatic sarcoma | Phase I/II MSKCC-10049 10-049,8406, NCT01154452 | Sponsor: NCI Lead Organisation: Memorial Sloan-Kettering Cancer Centre | Age: 18 and over Advanced sarcoma (Phase Ib) Advanced, metastatic sarcoma (Phase II) Expected enrolment (EE)120 | (i) To determine maximum tolerated dose of RO4929097 when combined with GDC-0449 in patients with advanced sarcoma (Phase Ib). (ii) To assess progression free survival (PFS) of patients with advanced, metastatic sarcoma treated with RO4929097 with or without GDC-0449. |
Phase II study of AuroraA Kinase Inhibitor MLN8237 in paediatric patients with recurrent or refractory solid tumours or leukaemia | Phase II COG-ADVL0921 ADVL0921 NCT01154816 | Sponsor: NCI Lead Organisation: Children's Oncology Group | Age: 1-21 years Entry criteria includes patients with histological confirmed Ewing sarcoma/peripheral primitive neuroectodermal tumour EE 190 | Assess objective response rate in paediatric patients |
Phase II study of Cixutumumab in patients with relapsed or refractory solid tumours Cixutumumab: A fully human IgG1 monoclonal antibody directed against IGF-1R * | Phase II COG-ADVL0821 ADVL0821 NCT00831844 | Sponsor: NCI Lead Organisation: Children's Oncology Group | Age: 6 months-30 years Entry criteria includes patients with histological confirmed Ewing sarcoma/peripheral primitive neuroectodermal tumour EE140 | (i) Assess response rate (ii) Toxicity Secondary outcome: Relationship between tumour expression of IGF-I, IGF-II, and IGF-IR and response* |
Phase II study of MK8669 in patients with metastatic bone or soft-tissue sarcoma (8669-030) MK8669 is a small molecule mTOR inhibitor and rapamycin analogue. mTOR is a serine/threonine kinase located downstream of the PI3K/Akt signalling pathway | Phase II | Sponsor: Pharmaceutical/Industry Trial sites located in Japan | Age: 13 and over Exclusion criteria include CNS metastasis (unless successfully treated), prior treatment with rapamycin or rapamycin analogues, on-going therapeutic toxicity from anticancer treatment, intercurrent or historic disease that may potentially confound results | Evaluation of MK 8669 when administered as maintenance therapy to patients with metastatic bone or soft-tissue sarcoma in Japan |
IMC-A12 in combination with temsirolimus (CCI-779) in patients with advanced cancers | Phase I 2007-0595 MDA-2007-0595 8109 NCT00678223 NCT00678769 | Sponsor: NCI Lead organisation: M.D. Anderson Cancer Centre, University of Texas | Age: 16 and over 3-6 participants each dose level of IMC-A12 in combination with temsirolimus | (i) To establish the highest tolerable dose combination of IMC-A12 and temsirolimus that can be given to patients with advanced or metastatic cancer. (ii) Establish drug safety. Tolerability of dose scheduling Biomarker studies incorporated |
A phase I study of NK cell infusion following allogeneic peripheral blood stem cell transplantation from related or matched unrelated donors in paediatric patients with solid tumours and leukaemia's | Phase I 110073 11-C-0073 NCT01287104 | NCI | Age: 4-35 years Paediatric solid tumours (if ESFT must have ultra-high risk ESFT) Re: EWS; (i) If at initial diagnosis has bone or bone marrow metastasis may be enrolled if completed standard front line therapy (SFLT) that includes vincristine, cyclophosphamide, adriamycin, ifosfamide and etoposide (ii) Patients with recurrence of tumour at any site less than 1 year after completing SFLT or with subsequent recurrence any time after completing SFLT (iii) Patients with progressive or persistent disease while receiving standard front line chemotherapy | (i) To determine the safety, effectiveness, and immune system response of giving NK white blood cells to individuals who have received allogeneic HSCT. (ii) To identify possible treatment related side effects. Background: Based on laboratory evidence NK cells following allogeneic PBSCT may have a beneficial anti-cancer therapeutic effect |
Studies of Temozolamide in combination with topotecan in refractory and relapsed paediatric solid tumours | Phase II CSET 2008/1378 NCT 00918320 | Lead organization: Institut Gustave Roussy | Age: 6 months - 20 years. Eligibility criteria include: Confirmed paediatric solid tumour, relapsed/refractory tumours in which SFLT has failed, not more than 2 lines of prior chemotherapy, CT/MRI measurable disease | To determine that the combination of topotecan and temozolamide is effective in the treatment of relapsed and refractory solid neuroblastoma and other paediatric solid tumours. |
PCI-24781 in combination with doxorubicin to treat sarcoma A broad-spectrum phenyl hydroxamic acid inhibitor of histone deacetylase (HDAC). Inhibits several isoforms of HDAC causing accumulation of highly acetylated histones and induction of chromatin remodelling. It also inhibits homologous recombination (HR) activity by inhibiting the expression of RAD51 | Phase I, II | Lead organisation/Sponsor Massachusetts General Hospital | Age: 18 years and over PCI-24781 is considered to regulate genes involved in tumour growth. | To determine safety and maximum tolerated dose of PCI-24781 that can be safety given with doxorubicin (phase I) and the the safety and efficacy of PCI-24781 when combined with doxorubicin (phase II) in patients with advanced sarcomas. |
Study in localised and disseminated Ewing sarcoma | Phase III | Lead organisation/sponsor: Medizinische Klinik und Poliklinik A-Universitaetsklinikum Muenster, Germany | Age: 4-50 years EWING 2008 is a joint protocol of European and North American Ewing sarcoma study groups. Open to all patients diagnosed with Ewing sarcomas, localised or metastatic, who are considered eligible for neoadjuvant chemotherapy. | Standard Risk R1: Randomised trial High Risk R2: Randomized trial Very High Risk R3: Randomized trial Refer to NCI website for full study details |